Related Experiment Videos
Drugs versus placebo for dysthymia
1Department of Mental Health, Universidade Federal de Pelotas, Avenida Duque de Caxias, 250, Pelotas, Rio Grande do Sul, BRAZIL, 96100. mslima@nutecnet.com.br
The Cochrane Database of Systematic Reviews
|October 18, 2000
Summary
Pharmacological treatments effectively manage dysthymia, with various drug classes showing similar efficacy. Tricyclic antidepressants (TCAs) may increase adverse events and dropouts in patients with dysthymia.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Dysthymia is a chronic depressive disorder with less severity than major depression, characterized by continuous symptoms for at least two years.
- Understanding the efficacy of pharmacological interventions is crucial for managing this long-term condition.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) comparing drug treatments with placebo for dysthymia.
- To assess the efficacy and safety of different drug classes in treating dysthymic patients.
Main Methods:
- Comprehensive electronic searches of multiple databases (Cochrane Library, EMBASE, MEDLINE, PsycLIT, Biological Abstracts, LILACS) and other sources.
- Inclusion of RCTs focusing on drug versus placebo for dysthymia, excluding mixed or secondary depression.
- Independent data extraction, intention-to-treat analysis, and calculation of Relative Risks (RR), 95% confidence intervals (CI), Number Needed to Treat (NNT), and Number Needed to Harm (NNH).
Main Results:
- The review included 15 trials, indicating similar efficacy across different drug classes (TCA, SSRI, MAOI, others).
- Pooled RR for absence of treatment response was consistently below 1 across drug classes, with NNTs ranging from 2.9 to 4.7.
- Tricyclic antidepressants (TCAs) were associated with a higher likelihood of adverse events and dropouts compared to placebo.
Conclusions:
- Pharmacological treatments are effective for dysthymia, with no significant differences in efficacy between drug classes.
- While effective, TCAs may lead to more adverse events and dropouts.
- Further research is needed on quality of life and long-term outcomes for dysthymia, given its chronic nature.